GlassScriptPhysician profile
Sadye G Dexter
NPI 1831714906
$1,975.19
in general payments reported to CMS, 2019-2025
32 companies · $917 in 2025
The $917 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $925 · 2022: $132 · 2025: $917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $917.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $917.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $218.01 | 2021-2025 | |
| Novo Nordisk INC | $194.09 | 2021 | |
| Lilly USA, LLC | $172.40 | 2021-2025 | Kisunla, Amyvid, Zepbound |
| Boston Scientific Corporation | $132.40 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $128.51 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $125.82 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $104.30 | 2021-2025 | Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $98.30 | 2025 | Hyqvia |
| Eisai INC. | $70.16 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $63.90 | 2021 | |
| Glaxosmithkline, LLC. | $63.44 | 2021 | |
| Pfizer INC. | $61.76 | 2025 | |
| Neurocrine Biosciences, INC. | $56.86 | 2025 | |
| Tanabe Pharma America, INC. | $46.69 | 2025 | Radicava |
| Amgen INC. | $46.53 | 2025 | Uplizna |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $35.76 | 2021-2025 | Leqembi |
| Csl Behring | $35.08 | 2025 | Hizentra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.52 | 2021 | |
| Argenx US, INC. | $29.03 | 2025 | Vyvgart Hytrulo |
| Merck Sharp & Dohme LLC | $28.18 | 2021 | |
| Novartis Pharmaceuticals Corporation | $24.78 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $24.60 | 2025 | Rexulti |
| Amneal Pharmaceuticals LLC | $22.50 | 2025 | Crexont |
| Medtronic, INC. | $22.29 | 2025 | Intellis Adaptivestim |
| Paratek Pharmaceuticals, INC. | $22.21 | 2021 | |
| Ucb, INC. | $20.34 | 2025 | Rystiggo |
| Celgene Corporation | $20.15 | 2025 | Zeposia |
| Sk Life Science, INC. | $19.55 | 2025 | |
| Janssen Biotech, INC. | $16.19 | 2025 | |
| C2n Diagnostics, LLC | $14.00 | 2025 | Precivityad2 |
| Amarin Pharma, INC. | $13.41 | 2021 | |
| Currax Pharmaceuticals LLC | $12.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sadye Dexter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.